DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
CCL21-loaded 3D hydrogels for T cell expansion and differentiation
Recent achievements in the field of immunotherapy, such as the development of engineered T cells used in adoptive cell therapy, are introducing more efficient strategies to combat cancer. Nevertheless, there are still many limitations. For example, these T cells are challenging to manufacture, manipulate, and control. Specifically, there are limitations in producing the large amounts of therapeutic T cells needed for these therapies in a short period of time and in an economically viable manner. In this study, three-dimensional (3D) poly(ethylene) glycol (PEG) hydrogels covalently combined with low molecular weight heparin are engineered to resemble the lymph nodes, where T cells reproduce. In these hydrogels, PEG provides the needed structural and mechanical properties, whereas heparin is used as an anchor for the cytokine CCL21, which is present in the lymph nodes, and can affect cell migration and proliferation. The 3D structure of the hydrogel in combination with its loading capacity result in an increased primary human CD4+ T cell proliferation compared to the state-of-the-art expansion systems consisting of artificial antigen presenting cells. Thus, we present a new tool for adoptive cell therapy to help achieving the large numbers of cells required for therapy of selected phenotypes targeted against cancer cells, by mimicking the lymph nodes., We acknowledge D. P. Rosenblatt for proofreading this manuscript and the “Servei de Microscòpia” from UAB for assistance in the confocal microscopy. The authors are grateful for the financial support received from the Spanish Ministry of Economy and Competitiveness MINECO (MAT2016-80826-R, PID2019-105622RBI00, the “Ramón y Cajal” program (RYC-2017-22614), and a DOC-INIA fellowship), the Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) through the projects “Alycia” (Nr. BBN18PI01) and “Gels4ACT” (Nr. BBN20PIV02), Generalitat de Catalunya (SGR-918, SGR-229, CERCA Programme, and AGAUR for a pre‐doctoral fellowship (FI-AGAUR)), Fundació Marató de TV3 (Nr. 201812), and the European Social Fund. This research was also supported by the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union (FP7/2007–2013) through the grant agreement Nr. 600388 of REA with the Agency for Business Competitiveness ACCIÓ through a Tecniospring fellowship (TECSPR15-1-0015) and the European Union's Horizon 2020 research and innovation programme H2020-MSCA-COFUND-2016 (DOC-FAM, grant agreement Nr. 754397). The work was funded as well by the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck for Medical Research (Heidelberg, Germany). ICMAB-CSIC acknowledges support from the MINECO through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2015-0496; FIP fellowship). This work has been developed inside the biochemistry and biomedicine PhD program of UAB., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 MAT2016-80826-R
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-105622RBI00
,
EC / FP7 600388
,
EC / H2020 754397
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SEV-2015-0496